21 completed, 3 terminated, 2 active not recruiting. 26 Phase 3.
By phase and status
Follow brivaracetam: new trials by email Literature Review of brivaracetam trials Research Report on brivaracetam
Trials (filtered) newest first · largest first
All 26 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy Brivaracetam Film-coated tablet, Brivaracetam oral solution - Childhood Absence Epilepsy, Juvenile Absence Epilepsy | Phase 3 | Active not recruiting | 70 | 2024-07-10 | 2026-08-27 |
Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial brivaracetam, Placebo - Spinal Cord Injuries, Neuropathic Pain | Phase 3 | Completed | 44 | 2023-01-01 | 2026-03-18 |
A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy Brivaracetam Film-coated tablet, Brivaracetam oral solution - Childhood Absence Epilepsy, Juvenile Absence Epilepsy | Phase 3 | Completed | 84 | 2022-03-30 | 2025-10-22 |
A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy Brivaracetam, Placebo - Childhood Absence Epilepsy, Juvenile Absence Epilepsy | Phase 3 | Completed | 154 | 2021-07-29 | 2026-10-30 |
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures Brivaracetam - Epilepsy | Phase 3 | Active not recruiting | 84 | 2021-03-11 | 2026-11-17 |
Long-term Safety and Efficacy of Adjunctive Brivaracetam in Chinese Patients With Uncontrolled Focal Epilepsy Brivaracetam - Epilepsy, Focal | Phase 3 | Completed | 141 | 2021-02-07 | 2026-05-04 |
A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures Brivaracetam (BRV) intravenous (iv), Brivaracetam (BRV) oral - Electroencephalographic Neonatal Seizures | Phase 3 | Terminated | 9 | 2019-05-07 | 2024-04-08 |
A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization Brivaracetam - Partial Seizures With or Without Secondary Generalization, Epilepsy | Phase 3 | Completed | 10 | 2019-01-04 | 2021-04-13 |
A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy Placebo, Brivaracetam - Partial Seizures With or Without Secondary Generalization, Epilepsy | Phase 3 | Completed | 449 | 2017-08-22 | 2025-10-14 |
A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization Brivaracetam - Partial Seizures With or Without Secondary Generalization, Epilepsy | Phase 3 | Completed | 207 | 2017-08-05 | 2025-07-29 |
Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy Brivaracetam - Epilepsy | Phase 3 | Completed | 26 | 2012-10-01 | 2018-07-11 |
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV) Brivaracetam - Epilepsy | Phase 3 | Completed | 29 | 2012-07-01 | 2018-07-11 |
Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy Brivaracetam (BRV) - Epilepsy | Phase 3 | Completed | 257 | 2011-08-01 | 2025-10-20 |
Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy Brivaracetam tablets, Brivaracetam bolus, Brivaracetam infusion - Epilepsy | Phase 3 | Completed | 105 | 2011-08-01 | 2018-07-11 |
Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy Brivaracetam - Epilepsy | Phase 3 | Completed | 767 | 2011-05-11 | 2021-08-17 |
Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures Placebo, Brivaracetam, Antiepileptic drugs with market authorization available per country - Epilepsy | Phase 3 | Completed | 768 | 2010-12-01 | 2022-07-22 |
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Brivaracetam - Epilepsy | Phase 3 | Completed | 108 | 2008-11-01 | 2018-07-11 |
A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures Brivaracetam - Epilepsy | Phase 3 | Terminated | 88 | 2008-08-01 | 2018-07-11 |
A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures Brivaracetam - Epilepsy | Phase 3 | Terminated | 62 | 2008-08-01 | 2018-07-11 |
Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy Placebo, Brivaracetam - Epilepsy | Phase 3 | Completed | 480 | 2007-10-01 | 2018-04-03 |
Showing 20 of 26. Sign in to see all of them.
Conditions studied
Epilepsy (21) · Epilepsy, Absence (3) · Myoclonic Epilepsies, Progressive (2) · Myoclonus (2) · Unverricht-Lundborg Syndrome (2) · Epilepsies, Partial (1) · Neuralgia (1) · Spinal Cord Injuries (1)
Sponsors
UCB Pharma (8) · UCB Biopharma SRL (7) · UCB Pharma SA (6) · Jiangxi Qingfeng Pharmaceutical Co. Ltd. (1) · UCB BIOSCIENCES, Inc. (1) · UCB Biopharma S.P.R.L. (1) · UCB PHARMA Inc. (US) (1) · University of Minnesota (1)
Countries
United States (18) · Italy (14) · Germany (13) · France (12) · Spain (11) · Belgium (9) · Czechia (9) · Canada (8) · Hungary (8) · Poland (7) · Sweden (7) · Finland (6) · Japan (6) · Mexico (6) · United Kingdom (6)
Top investigators
Ricardo Battaglino, PhD (1) · Zhen Hong, MD (1)
Results publications
PMID 26899665, PMID 34218211, PMID 33461041, PMID 35285519, PMID 27265725, PMID 27335114, PMID 27589414, PMID 27608437, PMID 27988967, PMID 28004320, PMID 28236727, PMID 28279891, PMID 29414542, PMID 29908435, PMID 32432339, PMID 34155568, PMID 35582748, PMID 38788664, PMID 26471380, PMID 26666500, PMID 29486396, PMID 33780735, PMID 36435010, PMID 24116853, PMID 24256083, PMID 24446953, PMID 26432008, PMID 32221987, PMID 35844134, PMID 37597326, PMID 38049197, PMID 40549270, PMID 40737960, PMID 40944847
NIH funding
2008 (4), 2023 (2), 2004 (1), 2015 (1)